Navigation Links
EORTC presents European solution for effective cancer drug development
Date:7/1/2014

Drug developers are facing the perfect storm. They are confronted with major patent expiries, increased payer scrutiny, changing priorities, shifting business models, increased risk averseness, increased clinical trial costs, not to mention issues concerning R&D productivity. There needs to be a better way to identify new candidate drugs. There needs to be a new drug development pathway that is compatible with research aimed at understanding the biology of a cancer and simultaneously able to support the design and conduct of subsequent confirmatory trials, but building and maintaining such a drug development pathway is beyond the ability of individual organizations or companies. It has been argued that new forms of partnership as well as an integrated model of cancer research are needed. Now, in a paper published in Nature Reviews Clinical Oncology, the EORTC describes how collaborative molecular screening platforms could help serve these needs.

Collaborative molecular screening platforms offer a high quality integrated infrastructure for efficient screening of patients with cancer for specific molecular alterations. These identified alterations will define target populations for early trials with novel targeted agents. Pharmaceutical industry partners would be in a position to propose candidate drugs for clinical trials which could be plugged into the platform. Patients fulfilling the inclusion criteria for one or more trials would be notified by their physician and given the option of participating.

Dr. Denis Lacombe, EORTC Director and lead author of this paper says, "Collaborative molecular screening platforms will offer patients efficient access to new therapeutic agents. Clinical research will be turned on its head. Instead of designing trials which must find patients for a particular drug, the question will become which drug should be given to a particular subset of patients with an identified molecular alteration."

Collaborative molecular screening platforms are a winning proposition for all cancer drug development stakeholders. As information-sharing platforms they enable us to learn from our failures. They accommodate the integration of information from continuous risk assessments and pave the way for an adaptive licensing strategy. Importantly, they enhance the expertise of the constituent partners by combining their efforts within a cost-sharing model and could very well be the realization of personalized medicine.


'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. EORTC to present cancer research results at ASCO 2014
2. NCI, NCRI and EORTC outline risk-assessment approach for biomarker-driven cancer clinical trials
3. EORTC and SIOG update expert opinion on management of elderly patients with NSCLC
4. EORTC study shows value of HRQOL assessment in small cell lung cancer
5. Joint EORTC-ESTRO session to focus on current developments in soft tissue sarcoma treatment
6. EORTC Cancer in the Elderly Task Force investigates appropriate treatment for elderly patients
7. EORTC head & neck cancer trial shows assessing HRQOL is valuable to both patients and their doctors
8. Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial
9. Vaccination with GM2-KLH-QS21 does not improve outcome of melanomas patients in EORTC study
10. EORTC at 2013 ECCO-ESMO-ESTRO meeting in Amsterdam
11. Moderate dose radiotherapy effective in EORTC trial for patients with desmoid-type fibromatosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology: